An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep. 1996

H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.

Protective effects of the gp51 of bovine leukaemia virus (BLV) expressed by a recombinant baculovirus (rgp51) and synthetic multiple antigenic peptides (MAP) of T-helper, T-cytotoxic, and B-cell epitopes of gp51 were investigated against BLV challenge. Two and three sheep were immunized with rgp51 and a mixture of peptides with Freund's complete adjuvant, respectively. BLV was detected from all the immunized sheep at 2 weeks and showed peak levels at 4 weeks after the challenge. However, in two sheep immunized with the mixed peptides, the titer of BLV gradually decreased and one sheep eliminated BLV completely at 28 weeks after the challenge. These two sheep showed higher lymphocyte proliferative responses against the immunized peptides than the other sheep. One of the sheep also showed the specific cytotoxic lymphocyte activity against the BLV gp51-expressing target in vitro. These results suggest the possibility of the peptide vaccine for elimination of BLV in carrier animals in vivo.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D001909 Leukemia Virus, Bovine The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis. BLV,Bovine Leukemia Virus,Cattle Leukemia Virus,Leukemia Virus, Cattle,Virus, Bovine Leukemia,Virus, Cattle Leukemia
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
August 1991, The Journal of general virology,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
September 1997, Veterinary immunology and immunopathology,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
January 1978, Annales de recherches veterinaires. Annals of veterinary research,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
August 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
August 1996, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
April 1997, Leukemia,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
August 1989, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
November 2019, Veterinary research,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
January 2008, Berliner und Munchener tierarztliche Wochenschrift,
H Kabeya, and K Ohashi, and K Ohishi, and C Sugimoto, and H Amanuma, and M Onuma
June 2019, Polish journal of veterinary sciences,
Copied contents to your clipboard!